title: A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population.
abstract: BACKGROUND
  Cholera spread to Latin America in 1991; subsequently, cholera vaccination was considered as an interim intervention until long-term solutions involving improved water supplies and sanitation could be introduced. Three successive summer cholera outbreaks in northern Argentina and the licensing of the new single-dose oral cholera vaccine, CVD 103-HgR, raised questions of the cost and benefit of using this new vaccine.
  
  
  METHODS
  This study explored the potential benefits to the Argentine Ministry of Health of treatment costs averted, versus the costs of vaccination with CVD 103-HgR in the relatively confined population of northern Argentina affected by the cholera outbreaks. Water supplies and sanitation in this area are poor but a credible infrastructure for vaccine delivery exists.
  
  
  RESULTS
  In our cost-benefit model of a 3-year period (1992-1994) with an annual incidence of 2.5 case-patients per 1000 population and assumptions of vaccine efficacy of 75% and coverage of 75%, vaccination of targeted high risk groups would prevent 1265 cases.
  
  
  CONCLUSIONS
  Assuming a cost of US$602 per treated case and of US$1.50 per dose of vaccine, the total discounted savings from use of vaccine in the targeted groups would be US$132,100. The projected savings would be altered less by vaccine coverage (range 75-90%) or efficacy (60-85%) changes than by disease incidence changes. Our analysis underestimated the true costs of cholera in Argentina because we included only medical expenditures; Indirect losses to trade and tourism had the greatest economic impact. However, vaccination with CVD 103-HgR was still cost-beneficial in the base case.
authors.affiliation: Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.
authors.forename: S T
authors.initials: ST
authors.lastname: Cookson
authors.forename: D
authors.initials: D
authors.lastname: Stamboulian
authors.forename: J
authors.initials: J
authors.lastname: Demonte
authors.forename: L
authors.initials: L
authors.lastname: Quero
authors.forename: C
authors.initials: C
authors.lastname: Martinez de Arquiza
authors.forename: A
authors.initials: A
authors.lastname: Aleman
authors.forename: A
authors.initials: A
authors.lastname: Lepetic
authors.forename: M M
authors.initials: MM
authors.lastname: Levine
mesh_terms: D000293:Adolescent; D000328:Adult; D001118:Argentina / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D002771:Cholera / Q000191:economics / Q000453:epidemiology* / Q000276:immunology; D022121:Cholera Vaccines / Q000008:administration & dosage* / Q000276:immunology; D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks / Q000191:economics* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D014611:Vaccination / Q000191:economics*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D022121:Cholera Vaccines; D014613:Vaccines, Attenuated